Trend
DailyDowntrend (confirmed)
4 hourSymmetric Triangle
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns up above $5.68
Key levels
Resistance$4.50
Resistance$3.61
Latest news & SEC filings
LegalNEXGEL regains Nasdaq minimum bid price compliance
LegalNEXGEL Regains Nasdaq Compliance
All NXGL news →NexGel produces water-based polymer gels that are cross-linked with electron beams. As a contract manufacturer, it supplies these gels to other companies that use them in skin patches, dressings, and beauty items. The company also sells its own consumer brands, including Medagel, Kenkoderm, and Silly George, through online, retail, and medical channels. It operates in the United States and is developing surgical and medical tape products.
Based on the company's 10-K filed Mar 31, 2026.
Nasdaq · Healthcare
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for NXGL.
Start Free Trial →Valuation Verdict
FAIR
Methods Used
P/B
Fair Value
$0.17
26
Moat Score
NONE
4/9
Piotroski Score
-2.5
Altman Z-Score
Insider Signal
SELLING
0 buys / 7 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Levy Adam R. | director officer | Sale | 3,000 | $2K | Jun 11, 2026 |
| Levy Adam R. | director officer | Sale | 3,000 | $2K | Jun 8, 2026 |
| Levy Adam R. | director officer | Sale | 3,000 | $2K | Jun 4, 2026 |
| Levy Adam R. | director officer | Sale | 2,000 | $1K | Jun 1, 2026 |
| Levy Adam R. | director officer | Sale | 3,000 | $2K | May 29, 2026 |
| Levy Adam R. | director officer | Sale | 7,000 | $4K | May 28, 2026 |
| Levy Adam R. | director officer | Sale | 3,000 | $2K | May 27, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
31.5%
3yr Revenue CAGR
77.3%
EPS Growth YoY
24%
FCF Growth YoY
68.0%
Revenue Trend
STRONG
SEPT Investing tracks real-time dark pool institutional trades for NXGL, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 17:51:18 | $3.74 | 1,000 | $$4K | BUY |
| 16:05:34 | $3.78 | 1,000 | $$4K | BUY |
| 14:30:12 | $3.80 | 1,315 | $$5K | BUY |
| 16:45:58 | $3.65 | 1,231 | $$4K | SELL |
| 16:27:44 | $3.72 | 1,487 | $$6K | BUY |
5 dark pool trades shown · $$23K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for NEXGEL, INC. (NXGL) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings intelligence, and a complete investment thesis with entry and exit recommendations.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →NEXGEL, INC. (NXGL) is at $3.50, down 9.79% (-$0.38) at the Nov 6, 2026 close.
Latest NXGL news — Oct 28, 2026: NEXGEL regains Nasdaq minimum bid price compliance · Oct 27, 2026: NEXGEL Regains Nasdaq Compliance
Analyst ratings for NXGL: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
NXGL last reported on Aug 17, 2026: EPS -$0.40 vs -$0.12 expected — a miss of 233.3%.
Resistance: $3.61, $4.50, $5.90.
Insider activity: SELLING, 0 buys and 7 sells in the last 90 days.
Oct 28, 2026: NEXGEL regains Nasdaq minimum bid price compliance · Oct 27, 2026: NEXGEL Regains Nasdaq Compliance